Science Corporation: PRIMA Retinal Implant Demonstrates Subretinal Reading in Stargardt Patient

Science Corporation has successfully implanted its wireless photovoltaic retinal prosthesis into its first human patient diagnosed with Stargardt disease. Announced by chief executive officer Max Hodak during TechCrunch Disrupt 2026 in San Francisco, the clinical milestone marks the first time the company's PRIMA microchip has been deployed to treat inherited juvenile macular degeneration rather than age-related geographic atrophy.

The surgical procedure took place in May 2026 at the Sydney Eye Hospital in Australia, conducted in partnership with the Save Sight Institute. Following the operation, the patient began structured visual rehabilitation sessions. During the initial rehabilitation appointment, the patient resolved an individual letter; by the second clinical session, the subject demonstrated the ability to read a complete word through the engineered visual interface.

The Bioelectric Architecture Behind Wireless Subretinal Photodiodes

Science Corporation's approach treats the human retina as an accessible peripheral component of the central nervous system. Rather than drilling into the skull to insert mechanical electrode arrays into brain tissue, the PRIMA system interfaces directly with surviving neural pathways inside the ocular cavity. The core implant consists of an autonomous two-millimeter by two-millimeter photovoltaic silicon array placed beneath the retina through a standardized one-hour vitreoretinal surgery.

Patients interact with their environment by wearing custom camera-equipped glasses. The exterior hardware captures optical visual data and transmits real-time infrared light pulses directly onto the subretinal chip. These miniature silicon photodiodes passively convert incoming infrared photons into localized electrical currents without requiring any implanted batteries or trans-scleral power wiring. The resulting electrical charges stimulate surviving bipolar and horizontal cells in the inner retina, allowing bioelectric potentials to travel along the intact optic nerve to the visual cortex.

"The retina is part of the central nervous system," Hodak stated on stage at TechCrunch Disrupt. "We consider cochlear implants, retinal prostheses, motor prostheses, these are all different types of BCIs. One of the nice things about this device approach, when I was saying the brain's a computer, vision is electrical potential, like electrical activity down the optic nerve. That's all vision is to the brain, and so if you can get the optic nerve to signal the rest of the brain correctly, then you can provide vision to it."

Anatomical Bounds and the Physics of the Straw View

Stargardt disease presents a distinct anatomical profile that makes subretinal stimulation viable. The inherited condition causes progressive degeneration of light-sensing photoreceptors in the outer retina, yet typically leaves inner retinal architecture and ganglionic signaling pathways intact. An estimated 150,000 individuals worldwide suffer from central vision loss caused by Stargardt disease, a genetic disorder for which no curative pharmaceuticals currently exist.

While the clinical outcome demonstrates functional word recovery, physical hardware dimensions currently impose strict geometric constraints on visual perception. The two-millimeter by two-millimeter PRIMA microchip occupies an active surface area of 4.00 square millimeters. Given that the anatomical human macula measures approximately 5.5 millimeters in diameter—representing an area of 23.76 square millimeters—the existing implant covers just 16.8 percent of the patient's macular zone. This limited footprint restricts the reconstructed visual field to a narrow central window.

Hodak addressed these perceptual boundaries directly during his presentation. "The device that this patient has is a two millimeter by two millimeter implant placed under the in the back of the eye, and so it's like looking through a straw," Hodak explained. "It is not a big field of view color vision. It's a patch in their central vision where . . .it's black and white, but it is sharp. It's high-contrast sharp, and so they can see a couple letters at a time. The next step is to make the field of view bigger. So to make a bigger implant, you have to deal with the curvature of the eye, and we need to make the electrodes smaller so that we get closer to native levels of detail."

Strategic Divergence from Neuralink's Cortical Penetration Model

The deployment of the PRIMA implant illustrates a distinct strategic division within the neurotechnology industry. Hodak previously co-founded Neuralink alongside Elon Musk and served as its president until his departure in 2021. While Neuralink pursued direct cortical intervention—utilizing surgical robots to insert thousands of flexible polymer electrode threads directly into brain parenchyma—Science Corporation has prioritized less invasive afferent pathways that stimulate existing sensory nerves.

To accelerate its translational pipeline, Science Corporation acquired the intellectual property, patents, and clinical trial portfolio of French bioelectronics developer Pixium Vision in April 2024, following approval from the Paris Commercial Court. The acquisition enabled Science Corporation to absorb mature clinical validation data from the European PRIMAvera study, where the device had already earned commercial CE Mark certification for patients suffering from geographic atrophy associated with dry age-related macular degeneration.

By repurposing an approved subretinal hardware platform for inherited monogenic blindness, the company establishes an immediate clinical track record. This commercial foothold provides operational stability while the engineering team develops experimental cortical surface sensors for broader neurological rehabilitation. Unlike penetrating intracortical microelectrodes that risk triggering glial scarring and tissue degradation over extended implantation periods, passive subretinal photovoltaics avoid cellular disruption within the cerebral hemispheres.

Curvature Constraints and the Multi-Year Path to Native Acuity

Scaling subretinal prosthetics beyond the present 16.8 percent macular footprint introduces acute mechanical obstacles. The interior curvature of the posterior eye prevents engineers from simply inserting wider flat silicon wafers beneath the retina without risking mechanical tension or retinal detachment. Future hardware iterations must transition toward flexible, segmented substrates or micro-mosaics capable of conforming to ocular spherical geometry.

Furthermore, approaching native visual acuity requires substantial reductions in electrode pitch to activate individual bipolar cells while preventing lateral electrical cross-talk. Science Corporation projects human clinical trials for its next-generation implant within twelve months, alongside a five-year target to approach native acuity levels. The timeline remains tethered to long-term regulatory clearances from the United States Food and Drug Administration and sustained cellular stability in ongoing Australian clinical trials.